Myocardial Solutions Announces Initial Enrollment for New, Fast Cardiac MRI Stress Test

RALEIGH, N.C., Aug. 3, 2016 /PRNewswire/ -- Myocardial Solutions, Inc. ("MSI") announced its first patient enrollment in a study comparing cardiac SENC stress testing to Magnetic Resonance Image (MRI) CINE stress testing. This study is being performed in four sites, two in the United States and two in Europe on Philips MRI scanners. This multi-center study is confirming the results of a comparative single site study performed in Heidelberg, Germany on 320 patients. The goal of the study is to compare SENC results for consistency against MRI CINE results which to date has been the industry gold standard for stress testing performance. However, MRI CINE is time intensive and has a small market share.

The corporate goal is to commercialize a competitive stress testing alternative to the market leader, cardiac nuclear stress testing, because of its well documented limitations. These limitations include long procedure times, patient radiation exposure, excessive false positives leading to unnecessary patient heart catheterizations, and high operating costs. MSI's SENC technology is fast (under 15 minutes), easy to perform, provides quantitative results, and may substantially reduce false positives associated with nuclear testing.

"The study is underway. We have used SENC in the past and like the speed, ease and accuracy it lends to Cardiac Magnetic Resonance ("CMR").  We are very optimistic that the SENC outcome data will be comparative to MRI CINE obtained in the Heidelberg study," said Dr. Amit Patel, Principal Investigator and Cardiologist at the University of Chicago. Patel went on to say, "Our goal is to investigate a new, safe, fast and competitive CMR cardiac stress test that will better identify patients who will benefit from cardiac catheterization, improve operating productivity and reduce hospital costs."

About Myocardial Solutions, Inc.:

The Company was founded in January of 2016 to commercialize software applications for fast processing of CRM imaging with objective quantified results. The objective is to create wide adoption of CMR diagnostics for better informed clinical decisions.

The Company's SENC technology is not presently FDA cleared, and has not been commercialized.

Contact:

Linda Horne

919-459-9102

http://myocardialsolutions.com/

SOURCE Myocardial Solutions, Inc.